---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic impact on families"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic impact on families. Topics: Informal care and caregiver productivity costs: HDBOI study (2020 euros), Informal caregiver time and objective burden: France, Caregiver employment and work productivity: HDBOI caregivers, Caregivers of people with advanced HD in North America: systematic literature review, and 5 further topics. 9 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of Huntington's disease on Families

<a id="topic-2.2.1.8.3-1"></a>

### Informal care and caregiver productivity costs: HDBOI study (2020 euros)

> “Indirect costs for informal care were calculated as the total number of hours per week of informal care multiplied by the number of weeks per year. Total number of hours per year was multiplied by the country average salary per hour.”
> “Caregiver state support accounted for 58%–75% of all direct nonmedical costs. Indirect costs were driven by lost productivity for PwHD (34%–42%) and costs of informal care requirements (40%–42%; Appendix Table A2).”

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

| Cost component | Early stage, mean (SD) and n | Mid stage, mean (SD) and n | Advanced stage, mean (SD) and n |
| --- | --- | --- | --- |
| Informal care | “€27,760 (€37,790) n = 121” | “€30,243 (€37,046) n = 120” | “€37,758 (€45,515) n = 83” |
| Lost productivity, caregiver | “€18,225 (€19,864) n = 33” | “€12,988 (€15,621) n = 46” | “€17,280 (€19,266) n = 49” |
| State support, caregiver | “€5134 (€5834) n = 22” | “€5897 (€5098) n = 36” | “€4778 (€3359) n = 43” |

Source: [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/)

<a id="topic-2.2.1.8.3-2"></a>

### Informal caregiver time and objective burden: France

> “We included 80 ICs (mean [SD] age 57 [12.9] years, 60% women) in charge of 80 individuals with early to advanced stage HD”
> “The mean hours of informal care time was high: 7.3 (7.9) h/day (range 0-24); the mean professional home care was 2.8 (2.8) h/day (range 0.1-12.3).”
> “The burden was partially related to the multiplex caregiving status (19%). Protective factors lowering the IC burden included the absence of financial hardship (57%), a strong social network (16%) and keeping active on the job market outside home (46%).”

Source: [Bayen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36055643/)

<a id="topic-2.2.1.8.3-3"></a>

### Caregiver employment and work productivity: HDBOI caregivers

> “A total of 37 (7%) respondents had to stop working because of their caregiving duties and 206 (41%) reported that their duties have impacted their career.”
> “Of the 206, approximately 59% were prevented from working more hours, 54% prevented from career progression, and 19% were required to choose an alternative career (See Table 3).”
> “High levels of informal care were reported, with an average of 34 hours of informal care per week.”
> “Overall impairment in caregiver daily activities increased with participant’s disease severity: 42% in ES, 48% in MS, and 52% in AS.”

Source: [Willock et al. (2021)](https://www.ispor.org/docs/default-source/euro2021/ispor-wpai-caregiver-poster-final-version-pdf.pdf)

<a id="topic-2.2.1.8.3-4"></a>

### Caregivers of people with advanced HD in North America: systematic literature review

| Caregiver outcome | Quoted value |
| --- | --- |
| Mean time spent as primary carer (years) | “10.2 years” |
| Total hours of formal care per week | “43 hours” |
| Total hours of informal care per week | “41 hours” |
| Prevented career progression | “51%” |
| Prevented from working more hours | “70%” |
| Overall work productivity loss | “54%” |

Source: [Knott et al. (2024)](https://www.ispor.org/docs/default-source/intl2024/ispor24tangee72poster139078-pdf.pdf)

> “Caregivers often give up their job, change careers, or reduce their hours to accommodate the long hours required to provide LTC.”

Source: [Knott et al. (2024)](https://www.ispor.org/docs/default-source/intl2024/ispor24tangee72poster139078-pdf.pdf)

<a id="topic-2.2.1.8.3-5"></a>

### Informal care as a share of societal cost: United Kingdom and Norway

> “Informal care was the largest driver of costs across all stages of HD; thus there is a need to also consider the needs of carers when planning services for people with HD.”

Source: [Jones et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5096063/)

> “Our results highlight the crucial role the informal caregivers play in the care provided to HD patients in all disease phases. Future research should focus on the estimation of productivity loss among informal caregivers.”

Source: [van Walsem et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9753307/)

<a id="topic-2.2.1.8.3-6"></a>

### Out-of-pocket financing by families: Peru

> “Direct non-healthcare costs represented 78.3% of total cost, indirect costs 14.4% and direct healthcare costs the remaining 7.3%.”
> “Direct costs were primarily financed by patients and their families.”

Source: [Silva-Paredes et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6937635/)

<a id="topic-2.2.1.8.3-7"></a>

### Juvenile-onset HD: costs to the NHS and to families (England and Wales, 2020 pounds)

> “The overall mean JoHD cost to the NHS per year (2020) was £126,966 which varied according to disease severity, costing just under £11,000 in mild disease, £132,419 in moderate disease, and £221,797 in advanced JoHD.”
> “The proportion of indirect costs to families and carers was 64% for mild disease and 17% for advanced disease.”

Source: [Young et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13071353/)

| Severity | “No. accessing” | Costs to family, “Mean (SD)” |
| --- | --- | --- |
| Mild | “9 (90%)” | “£19,269 (£17,995)” |
| Moderate | “7 (100%)” | “£33,118 (£45,657)” |
| Advanced | “14 (100%)” | “£48,696 (£55,825)” |
| All | “32 (97.0%)” | “£35,993 (£43,918)” |

Source: [Young et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13071353/)

<a id="topic-2.2.1.8.3-8"></a>

### Family financial and care needs: ICER stakeholder input

> “Many people with HD require care in a long-term care facility because of the heavy caregiving needs, and caregivers often need to change their career or work less to accommodate the needs of the individual with HD”
> “clinicians emphasized the importance of multidisciplinary care, including neurologists, psychiatrists, therapists, social workers, and geneticists, as families need assistance not only with medical issues but also with financial issues such as long-term care and life insurance, and testing for family members.”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/08/Huntingtons-Disease_Draft-Scope_For-Publication_082026_For-Publication.pdf)

<a id="topic-2.2.1.8.3-9"></a>

### At-risk family members: genetic discrimination in insurance

> “Discrimination was reported by 93 respondents (39.9%). Reported experiences occurred most often in insurance (29.2%), family (15.5%), and social (12.4%) settings.”
> “Family history of Huntington's disease, rather than the result of genetic testing, was the main reason given for experiences of genetic discrimination.”

Source: [Bombard et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2694258/)

> “Across all three countries, a total of 46.2% of respondents report genetic discrimination or stigma based on either their family history of HD or genetic testing for the HD gene mutation.”
> “We report on the overall incidence of discrimination and stigma in the domains of insurance (25.9%), employment (6.5%), relationships (32.9%), and other transactions (4.6%) in the United States, Canada, and Australia combined.”

Source: [Erwin et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3593716/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
